INSM - Insmed Inc Stock Price, Fair Value and News

25.27USD+1.16 (+4.81%)Market Closed

Market Summary

USD25.27+1.16

Market Closed

4.81%

INSM Stock Price

View Fullscreen

INSM RSI Chart

INSM Valuation

Market Cap

3.8B

Price/Earnings (Trailing)

-5.01

Price/Sales (Trailing)

12.29

EV/EBITDA

-6.71

Price/Free Cashflow

-6.83

INSM Price/Sales (Trailing)

INSM Profitability

EBT Margin

-244.76%

Return on Equity

225.83%

Return on Assets

-56.37%

Free Cashflow Yield

-14.64%

INSM Fundamentals

INSM Revenue

Revenue (TTM)

305.2M

Rev. Growth (Yr)

41.13%

Rev. Growth (Qtr)

5.84%

INSM Earnings

Earnings (TTM)

-749.6M

Earnings Growth (Yr)

-16.2%

Earnings Growth (Qtr)

-17.07%

Breaking Down INSM Revenue

Last 7 days

-3.4%

Last 30 days

-4.4%

Last 90 days

-7.8%

Trailing 12 Months

33.6%

How does INSM drawdown profile look like?

INSM Financial Health

Current Ratio

4.12

Debt/Equity

-3.48

Debt/Cashflow

-0.46

INSM Investor Care

Shares Dilution (1Y)

8.86%

Diluted EPS (TTM)

-5.34

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	257.5M	269.5M	280.8M	305.2M
2022	201.4M	221.2M	242.2M	245.4M
2021	167.8M	170.6M	173.8M	188.5M
2020	151.4M	163.9M	168.7M	164.4M
2019	37.2M	64.5M	100.6M	136.5M
2018	3.5M	6.1M	8.5M	17.3M
2017	588.0K	593.0K	781.0K	1.6M
2016	408.0K	504.0K	567.0K	604.0K
2015	4.0M	2.1M	178.0K	261.0K
2014	9.6M	7.7M	5.8M	0
2013	5.3M	7.4M	9.4M	11.5M
2012	3.2M	0	0	0
2011	6.6M	5.7M	4.3M	4.4M
2010	0	9.2M	8.1M	6.9M
2009	0	0	0	10.4M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Insmed Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 28, 2024	sharoky melvin md	gifted	-	-	-3,600	-
Feb 28, 2024	sharoky melvin md	gifted	-	-	1,200	-
Feb 28, 2024	lewis william	acquired	629,000	12.58	50,000	chair and ceo
Jan 12, 2024	adsett roger	sold	-150,336	28.63	-5,251	chief operating officer
Jan 12, 2024	flammer martina m.d.	sold	-133,616	28.63	-4,667	chief medical officer
Jan 10, 2024	adsett roger	sold	-102,190	28.9	-3,536	chief operating officer
Jan 10, 2024	flammer martina m.d.	sold	-35,980	28.9	-1,245	chief medical officer
Jan 09, 2024	flammer martina m.d.	sold	-136,782	29.01	-4,715	chief medical officer

Which funds bought or sold INSM recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 22, 2024	RAYMOND JAMES & ASSOCIATES	added	50.8	407,901	1,682,090	-%
Apr 22, 2024	MetLife Investment Management, LLC	added	5.12	504,984	2,245,160	0.02%
Apr 22, 2024	Stonegate Investment Group, LLC	reduced	-53.57	-18,053	13,923	-%
Apr 18, 2024	Requisite Capital Management, LLC	new	-	678,250	678,250	0.15%
Apr 18, 2024	Diversified Trust Co	added	5.23	-50,293	588,286	0.02%
Apr 18, 2024	Allspring Global Investments Holdings, LLC	reduced	-62.27	-236,569	116,686	-%
Apr 18, 2024	Hexagon Capital Partners LLC	unchanged	-	-2,240	15,735	-%
Apr 18, 2024	Park Place Capital Corp	unchanged	-	-444	3,120	-%
Apr 18, 2024	SJS Investment Consulting Inc.	unchanged	-	-50.00	353	-%
Apr 17, 2024	Fox Hill Wealth Management	added	3.82	-4,264	145,857	0.10%

Are Funds Buying or Selling INSM?

Are funds buying INSM calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own INSM

No. of Funds

Unveiling Insmed Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 16, 2024	t. rowe price investment management, inc.	4.1%	5,850,606	SC 13G/A
Feb 14, 2024	t. rowe price investment management, inc.	4.1%	5,850,606	SC 13G
Feb 14, 2024	price t rowe associates inc /md/	7.5%	10,779,225	SC 13G/A
Feb 13, 2024	vanguard group inc	9.87%	14,125,521	SC 13G/A
Jan 25, 2024	blackrock inc.	8.0%	11,492,282	SC 13G/A
Jan 22, 2024	state street corp	4.15%	5,929,933	SC 13G/A
Nov 13, 2023	vanguard group inc	10.07%	14,410,356	SC 13G/A
Feb 14, 2023	t. rowe price investment management, inc.	6.2%	8,374,675	SC 13G
Feb 14, 2023	price t rowe associates inc /md/	7.4%	9,977,911	SC 13G/A
Feb 14, 2023	palo alto investors lp	4.33%	5,871,291	SC 13G/A

Recent SEC filings of Insmed Inc

View All Filings

Date Filed	Form Type	Document
Apr 01, 2024	DEFA14A	DEFA14A
Apr 01, 2024	DEF 14A	DEF 14A
Mar 11, 2024	8-K	Current Report
Feb 29, 2024	4	Insider Trading
Feb 29, 2024	4	Insider Trading
Feb 22, 2024	8-K	Current Report
Feb 22, 2024	424B5	Prospectus Filed
Feb 22, 2024	10-K	Annual Report
Feb 16, 2024	SC 13G/A	Major Ownership Report
Feb 14, 2024	SC 13G/A	Major Ownership Report

Peers (Alternatives to Insmed Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.2B	6.8B	2.33%	-21.90%	-8.74	6.02	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.4B	1.8B	-0.30%	-28.67%	-41.79	10.06	76.23%	61.08%
BMRN	17.4B	2.4B	8.14%	-4.26%	103.61	7.18	15.42%	18.43%
INCY	11.6B	3.7B	-9.39%	-31.39%	19.4	3.14	8.87%	75.42%
MID-CAP
APLS	5.9B	396.6M	-12.04%	-45.12%	-11.11	14.81	425.83%	18.94%
BBIO	4.5B	-	-13.93%	67.39%	-6.85	60.35	54.84%	-34.79%
AXSM	3.5B	270.6M	-9.40%	-0.33%	-14.47	12.79	440.80%	-27.84%
ARWR	2.9B	240.7M	-12.61%	-20.79%	-9.93	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-6.74%	-16.88%	-45.01	3.8	40.45%	71.62%
SMALL-CAP
CPRX	1.7B	398.2M	-6.36%	-10.84%	24.31	4.36	85.90%	-14.05%
NVAX	587.8M	983.7M	-10.64%	-48.02%	-1.08	0.6	-50.36%	17.16%
CRBP	396.0M	881.7K	8.01%	271.09%	-8.88	466.16	-77.61%	-5.33%
INO	242.4M	4.9M	-10.76%	0.48%	-1.79	49.8	-54.97%	51.71%
IBIO	6.7M	2.1M	76.15%	62.71%	-0.25	2.14	-13.45%	66.37%

Insmed Inc News

Latest updates

Insmed Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	5.8%	83,693,000	79,072,000	77,229,000	65,214,000	59,300,000	67,730,000	65,221,000	53,107,000	56,124,000	46,757,000	45,366,000	40,214,000	41,415,000	43,643,000	42,495,000	36,860,000	45,708,000	38,885,000	29,972,000	21,902,000	9,835,000
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	33,021,000	32,545,000	28,422,000	37,002,000	32,448,000	25,053,000	17,752,000	7,412,000
Costs and Expenses	15.5%	261,965,000	226,740,000	312,757,000	213,372,000	210,775,000	195,427,000	153,537,000	142,940,000	155,202,000	150,374,000	133,932,000	124,047,000	135,953,000	99,866,000	96,609,000	97,217,000	108,296,000	88,936,000	87,219,000	87,261,000	97,557,000
S&GA Expenses	-1.2%	89,530,000	90,626,000	84,431,000	79,914,000	73,479,000	75,583,000	59,974,000	56,748,000	65,266,000	60,280,000	57,177,000	51,550,000	56,019,000	46,585,000	49,663,000	51,346,000	50,206,000	53,347,000	52,433,000	54,810,000	53,960,000
R&D Expenses	25.5%	137,029,000	109,148,000	196,969,000	127,865,000	124,763,000	99,872,000	88,527,000	84,356,000	76,352,000	70,347,000	64,655,000	61,390,000	67,814,000	41,411,000	35,748,000	36,184,000	32,630,000	34,340,000	33,538,000	31,203,000	39,925,000
EBITDA Margin	4.9%	-2.16	-2.27	-2.33	-1.93	-1.83	-1.68	-1.73	-1.96	-2.05	-2.18	-1.94	-1.66	-	-	-	-	-	-	-	-	-
Interest Expenses	2.4%	20,784,000	20,288,000	20,619,000	20,003,000	16,445,000	3,353,000	3,357,000	3,291,000	11,350,000	11,245,000	10,319,000	7,559,000	7,499,000	7,185,000	7,469,000	7,411,000	7,348,000	6,846,000	6,785,000	6,726,000	6,667,000
Income Taxes	86.2%	1,013,000	544,000	500,000	483,000	118,000	372,000	500,000	400,000	-27,500	-2,600,000	600,000	239,000	634,000	300,000	400,000	36,000	327,000	100,000	100,000	200,000	104,000
Earnings Before Taxes	-16.8%	-185,063,000	-158,389,000	-244,279,000	-159,281,000	-159,998,000	-130,773,000	-95,144,000	-94,236,000	-113,019,000	-115,292,000	-116,699,000	-91,402,000	-101,592,000	-63,342,000	-61,426,000	-66,328,000	-52,664,000	-60,534,000	-66,424,000	-73,938,000	-91,506,000
EBT Margin	4.8%	-2.45	-2.57	-2.58	-2.12	-1.96	-1.79	-1.89	-2.18	-2.32	-2.45	-2.19	-1.89	-	-	-	-	-	-	-	-	-
Net Income	-17.1%	-186,061,000	-158,933,000	-244,809,000	-159,764,000	-160,123,000	-131,145,000	-95,645,000	-94,621,000	-112,978,000	-112,714,000	-117,321,000	-91,641,000	-102,213,000	-63,659,000	-61,854,000	-66,364,000	-52,988,000	-60,682,000	-66,514,000	-74,153,000	-91,573,000
Net Income Margin	4.7%	-2.46	-2.58	-2.58	-2.12	-1.96	-1.79	-1.88	-2.17	-2.31	-2.44	-2.20	-1.90	-	-	-	-	-	-	-	-	-
Free Cashflow	4.5%	-132,972,000	-139,187,000	-127,675,000	-149,701,000	-107,840,000	-90,410,000	-105,205,000	-106,862,000	-85,274,000	-76,926,000	-78,929,000	-129,462,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	0.4%	1,330	1,325	1,439	1,518	1,656	995	1,053	1,153	1,244	1,312	1,230	692	796	841	885	677	742	763	803	596	605
Current Assets	0.3%	929	927	1,052	1,129	1,273	632	675	756	837	959	1,038	501	623	667	707	493	555	596	649	455	519
Cash Equivalents	-1.0%	482	487	613	969	1,074	415	416	516	717	847	928	410	533	589	642	429	487	536	601	420	495
Inventory	6.8%	83.00	78.00	77.00	71.00	70.00	66.00	67.00	64.00	67.00	67.00	60.00	52.00	50.00	43.00	35.00	31.00	28.00	23.00	20.00	13.00	7.00
Net PPE	1.2%	65.00	65.00	62.00	60.00	56.00	54.00	54.00	53.00	53.00	53.00	54.00	53.00	54.00	55.00	57.00	59.00	60.00	53.00	39.00	28.00	23.00
Goodwill	0%	136	136	136	136	136	136	136	136	136	136	-	-	-	-	-	-	-	-	-	-	-
Liabilities	2.9%	1,662	1,614	1,595	1,562	1,568	1,025	1,009	1,033	833	807	699	491	520	484	480	470	481	459	446	452	396
Current Liabilities	14.7%	226	197	204	188	190	138	114	125	135	113	100	81.00	119	84.00	79.00	72.00	85.00	85.00	86.00	94.00	80.00
Long Term Debt	0.7%	1,155	1,148	1,140	1,132	1,125	785	784	783	567	558	549	362	356	351	346	341	336	331	326	321	317
LT Debt, Non Current	0.7%	1,155	1,148	1,140	1,132	1,125	785	784	783	567	558	549	362	356	351	346	341	336	331	326	321	317
Shareholder's Equity	-Infinity%	-331	-	-	-	88.00	-	44.00	120	410	505	531	202	276	357	405	207	262	304	357	144	208
Retained Earnings	-5.7%	-3,446	-3,260	-3,101	-2,856	-2,696	-2,536	-2,405	-2,309	-2,265	-2,152	-2,039	-1,922	-1,830	-1,728	-1,664	-1,602	-1,536	-1,483	-1,422	-1,356	-1,282
Additional Paid-In Capital	4.8%	3,113	2,971	2,945	2,809	2,782	2,507	2,449	2,429	2,674	2,656	2,569	2,123	2,105	2,084	2,069	1,809	1,797	1,787	1,779	1,500	1,490
Shares Outstanding	3.4%	148	143	143	136	136	120	120	119	112	110	110	103	-	-	-	-	-	-	-	-	-
Float	-	-	-	3,000	-	-	-	2,300	-	-	-	3,200	-	-	-	2,800	-	-	-	2,300	-	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	4.0%	-130,819	-136,333	-122,792	-146,303	-103,149	-89,828	-102,301	-105,161	-84,132	-75,445	-75,444	-128,281	-66,792	-58,668	-35,953	-57,935	-44,404	-52,368	-80,030	-73,847	-70,164
Share Based Compensation	-0.1%	19,983	19,993	18,359	16,443	14,950	15,654	14,259	12,823	11,520	12,231	11,735	10,535	8,779	8,909	9,468	9,002	5,888	6,794	7,353	6,936	6,035
Cashflow From Investing	-74.8%	1,803	7,147	-274,156	41,602	20,309	49,418	-2,904	-101,407	-51,218	-8,401	-3,485	-1,181	-1,515	-747	-1,881	-2,679	-13,038	-14,592	-10,610	-4,028	-4,751
Cashflow From Financing	9768.9%	123,263	1,249	44,326	-399	743,387	37,116	6,311	6,459	5,710	2,536	597,597	6,703	12,011	6,102	250,756	2,134	9,238	1,358	271,633	3,049	2,423

INSM Income Statement

2023-12-31

Consolidated Statements of Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Statement of Comprehensive Income [Abstract]
Product revenues, net	$ 305,208	$ 245,358	$ 188,461
Revenue from Contract with Customer, Product and Service [Extensible Enumeration]	Product [Member]	Product [Member]	Product [Member]
Operating expenses:
Cost of product revenues (excluding amortization of intangible assets)	$ 65,573	$ 55,126	$ 44,152
Cost, Product and Service [Extensible Enumeration]	Product [Member]	Product [Member]	Product [Member]
Research and development	$ 571,011	$ 397,518	$ 272,744
Selling, general and administrative	344,501	265,784	234,273
Amortization of intangible assets	5,052	5,053	5,052
Change in fair value of deferred and contingent consideration liabilities	28,697	(20,802)	7,334
Total operating expenses	1,014,834	702,679	563,555
Operating loss	(709,626)	(457,321)	(375,094)
Investment income	42,132	11,081	174
Interest expense	(81,694)	(26,446)	(40,473)
Change in fair value of interest rate swap	320	(1,526)	0
Loss on extinguishment of debt	0	0	(17,689)
Other income (expense), net	1,856	(5,939)	(3,330)
Loss before income taxes	(747,012)	(480,151)	(436,412)
Provision (benefit) for income taxes	2,555	1,383	(1,758)
Net loss	$ (749,567)	$ (481,534)	$ (434,654)
Net loss per share, Basic (in dollars per share)	$ (5.34)	$ (3.91)	$ (3.88)
Net loss per share, Diluted (in dollars per share)	$ (5.34)	$ (3.91)	$ (3.88)
Weighted average basic common shares outstanding (in shares)	140,433	123,035	112,111
Weighted average diluted common shares outstanding (in shares)	140,433	123,035	112,111
Net loss	$ (749,567)	$ (481,534)	$ (434,654)
Other comprehensive income (loss):
Foreign currency translation and other (losses) gains	(2,214)	303	775
Unrealized gain (loss) on marketable securities	713	(515)	0
Total comprehensive loss	$ (751,068)	$ (481,746)	$ (433,879)

INSM Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 482,374	$ 1,074,036
Marketable securities	298,073	74,244
Accounts receivable	41,189	29,713
Inventory	83,248	69,922
Prepaid expenses and other current assets	24,179	25,468
Total current assets	929,063	1,273,383
Fixed assets, net	65,384	56,491
Finance lease right-of-use assets	20,985	23,697
Operating lease right-of-use assets	18,017	21,894
Intangibles, net	63,704	68,756
Goodwill	136,110	136,110
Other assets	96,574	76,104
Total assets	1,329,837	1,656,435
Current liabilities:
Accounts payable and accrued liabilities	214,987	182,117
Finance lease liabilities	2,610	1,217
Operating lease liabilities	8,032	6,909
Total current liabilities	225,629	190,243
Debt, long-term	1,155,313	1,125,250
Royalty financing agreement	155,034	148,015
Contingent consideration	84,600	51,100
Finance lease liabilities, long-term	27,026	29,636
Operating lease liabilities, long-term	11,013	14,853
Other long-term liabilities	3,145	9,387
Total liabilities	1,661,760	1,568,484
Shareholders' equity:
Common stock, $0.01 par value; 500,000,000 authorized shares, 147,977,960 and 135,653,731 issued and outstanding shares at December 31, 2023 and December 31, 2022, respectively	1,480	1,357
Additional paid-in capital	3,113,487	2,782,416
Accumulated deficit	(3,446,145)	(2,696,578)
Accumulated other comprehensive (loss) income	(745)	756
Total shareholders' (deficit) equity	(331,923)	87,951
Total liabilities and shareholders' equity	$ 1,329,837	$ 1,656,435

About Insmed Inc

Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis, cystic fibrosis, and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary hypertension associated with interstitial lung disease and pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.

CEO	Mr. William H. Lewis J.D., M.B.A.
WEBSITE	insmed.com
INDUSTRY	Biotechnology
EMPLOYEES	736

Insmed Inc Frequently Asked Questions

What is the ticker symbol for Insmed Inc? What does INSM stand for in stocks?

INSM is the stock ticker symbol of Insmed Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Insmed Inc (INSM)?

As of Tue Apr 23 2024, market cap of Insmed Inc is 3.75 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of INSM stock?

You can check INSM's fair value in chart for subscribers.

What is the fair value of INSM stock?

You can check INSM's fair value in chart for subscribers. The fair value of Insmed Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Insmed Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for INSM so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Insmed Inc a good stock to buy?

The fair value guage provides a quick view whether INSM is over valued or under valued. Whether Insmed Inc is cheap or expensive depends on the assumptions which impact Insmed Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for INSM.

What is Insmed Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 23 2024, INSM's PE ratio (Price to Earnings) is -5.01 and Price to Sales (PS) ratio is 12.29. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. INSM PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Insmed Inc's stock?

In the past 10 years, Insmed Inc has provided 0.066 (multiply by 100 for percentage) rate of return.